Expert Review of Anticancer Therapy This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Hepatic artery infusion chemotherapy combined with the FOLFOX regimen for the treatment of hepatocellular carcinoma: recent advances and literature review
Expert Rev Anticancer Ther. 2024 Apr 24:1-12. doi: 10.1080/14737140.2024.2346624. Online ahead of print.ABSTRACTINTRODUCTION: The incidence of primary liver cancer (PLC) has experienced a significant global increase, primarily attributed to the rise in hepatocellular carcinoma (HCC). Unfortunately, HCC is often diagnosed in advanced stages, leaving patients with limited treatment options. Therefore, transformation therapy is a crucial approach for long-term survival and radical resection in patients with advanced HCC. Conversion therapy has demonstrated promise in the treatment of advanced HCC. When integrated with the FOL...
Source: Expert Review of Anticancer Therapy - April 23, 2024 Category: Cancer & Oncology Authors: Suqi Zhu Yahan Yu Mingqi Yang Xin Liu Mingkai Lai Jieren Zhong Xiaoguang Zhao Ligong Lu Yanyan Liu Source Type: research

Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies
CONCLUSIONS: We highlight important differences in clinical outcomes between CAR T-cell therapies. Axi-cel demonstrated improved overall survival compared to tisa-cel and liso-cel, and both axi-cel and liso-cel showed higher response rates compared to tisa-cel.PMID:38646700 | DOI:10.1080/14737140.2024.2343801 (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - April 22, 2024 Category: Cancer & Oncology Authors: Olalekan O Oluwole Sattva S Neelapu Markqayne D Ray Eve H Limbrick-Oldfield Sally W Wade Steve Kanters Anik R Patel Frederick L Locke Source Type: research

Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: Elacestrant as the poster-child
Expert Rev Anticancer Ther. 2024 Apr 20. doi: 10.1080/14737140.2024.2346188. Online ahead of print.ABSTRACTINTRODUCTION: Estrogen receptor positive (ER+) breast cancer is the most common breast cancer subtype, and therapeutic management relies primarily on inhibiting ER signaling. In the metastatic setting, ER signaling is typically targeted by selective estrogen receptor degraders (SERDs) or aromatase inhibitors (AIs), the latter of which prevent estrogen production. Activating ESR1 mutations are among the most common emergent breast cancer mutations and confer resistance to AIs.AREAS COVERED: Until 2023, fulvestrant was ...
Source: Expert Review of Anticancer Therapy - April 20, 2024 Category: Cancer & Oncology Authors: Jennifer C Keenan Arielle J Medford Charles S Dai Seth A Wander Laura M Spring Aditya Bardia Source Type: research

Navigating resistance to ALK inhibitors in the lorlatinib era: a comprehensive perspective on NSCLC
Expert Rev Anticancer Ther. 2024 Apr 21:1-15. doi: 10.1080/14737140.2024.2344648. Online ahead of print.ABSTRACTINTRODUCTION: The emergence of anaplastic lymphoma kinase (ALK) rearrangements in non-small cell lung cancer (NSCLC) has revolutionized targeted therapy. This dynamic landscape, featuring novel ALK inhibitors and combination therapies, necessitates a profound understanding of resistance mechanisms for effective treatment strategies. Recognizing two primary categories - on-target and off-target resistance - underscores the need for comprehensive assessment.AREAS COVERED: This review delves into the intricacies of ...
Source: Expert Review of Anticancer Therapy - April 17, 2024 Category: Cancer & Oncology Authors: Maria Gemelli Adriana Albini Gianpiero Catalano Matteo Incarbone Maria Cannone Emanuela Balladore Riccardo Ricotta Giuseppe Pelosi Source Type: research

Navigating resistance to ALK inhibitors in the Lorlatinib Era: a comprehensive perspective on NSCLC
Expert Rev Anticancer Ther. 2024 Apr 17. doi: 10.1080/14737140.2024.2344648. Online ahead of print.ABSTRACTINTRODUCTION: The emergence of anaplastic lymphoma kinase (ALK) rearrangements in non-small cell lung cancer (NSCLC) has revolutionized targeted therapy. This dynamic landscape, featuring novel ALK inhibitors and combination therapies, necessitates a profound understanding of resistance mechanisms for effective treatment strategies. Recognizing two primary categories - on-target and off-target resistance - underscores the need for comprehensive assessment.AREAS COVERED: This review delves into the intricacies of resis...
Source: Expert Review of Anticancer Therapy - April 17, 2024 Category: Cancer & Oncology Authors: Maria Gemelli Adriana Albini Gianpiero Catalano Matteo Incarbone Maria Cannone Emanuela Balladore Riccardo Ricotta Giuseppe Pelosi Source Type: research

The effect of age, sex, and eastern cooperative oncology group performance status on the efficacy and safety of immune checkpoint inhibitors in patients with hepatocellular carcinoma: a systematic review and meta-analysis
CONCLUSION: ICI therapy in HCC should not be restricted strictly to certain patients in age or sex categories, while HCC patients with higher ECOG PS may require closer medication or follow-up strategy during ICI therapy.PROSPERO REGISTRATION: CRD42024518407.PMID:38623811 | DOI:10.1080/14737140.2024.2341723 (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - April 16, 2024 Category: Cancer & Oncology Authors: Cheng-Long Han Bao-Wen Tian Lun-Jie Yan Zi-Niu Ding Hui Liu Guo-Qiang Pan Xiao Zhang Xin-Chen Mao Si-Yu Tan Rui-Zhe Li Dong-Xu Wang Zhao-Ru Dong Yu-Chuan Yan Tao Li Source Type: research

How to manage prolonged immune effector cell-associated hematotoxicity (ICAHT) related to BCMA-directed myeloma therapy
Expert Rev Anticancer Ther. 2024 Apr 16. doi: 10.1080/14737140.2024.2344650. Online ahead of print.NO ABSTRACTPMID:38626305 | DOI:10.1080/14737140.2024.2344650 (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - April 16, 2024 Category: Cancer & Oncology Authors: James A Davis Mary McGann Jessica Marini Hamza Hashmi Source Type: research

Do treatment patterns differ in those with early-onset colorectal cancer?
CONCLUSION: EOCRC patients are given more adjuvant chemotherapy, without a corresponding improvement in outcomes, highlighting a potential for increased treatment-related harms, particularly in stage 2 disease. Clinicians should be mindful of these biases when treating young cancer patients and need to carefully consider treatment-related harms.PMID:38619285 | DOI:10.1080/14737140.2024.2341731 (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - April 15, 2024 Category: Cancer & Oncology Authors: Oliver Waddell Yahsze Teo Nasya Thompson Andrew McCombie Tamara Glyn Frank Frizelle Source Type: research

A meta-analysis of UCA1 accuracy in the detection of bladder cancer
CONCLUSION: UCA1 could serve as a potential biomarker for BCa detection with good diagnostic performance. Besides, compared to UCA1 in blood, urine and tissue UCA1 exhibited higher diagnostic value. Further prospective clinical research is needed to corroborate the conclusion.PROSPERO REGISTRATION: CRD42023463210.PMID:38606888 | DOI:10.1080/14737140.2024.2342528 (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - April 12, 2024 Category: Cancer & Oncology Authors: Silei He Jiawen Xu Minlin Chen Jiajin Li Shiqian Li Jufeng Ye Source Type: research

Targeting GPRC5D in multiple myeloma
Expert Rev Anticancer Ther. 2024 Apr 16:1-10. doi: 10.1080/14737140.2024.2343114. Online ahead of print.ABSTRACTINTRODUCTION: The prognosis of multiple myeloma (MM) continues to improve. Recent progress in therapies, using immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and anti-CD38 monoclonal antibodies, has greatly improved patients' outcomes. Despite these advancements, relapses still happen often, and patients can become resistant to the usual treatments. Newer treatments, such as chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies (BsAbs) targeting B-cell maturation antigen (BCMA), h...
Source: Expert Review of Anticancer Therapy - April 12, 2024 Category: Cancer & Oncology Authors: Shatha Elemian Samer Al Hadidi Source Type: research

Are statins onco- suppressive agents for every type of tumor? A systematic review of literature
Expert Rev Anticancer Ther. 2024 Apr 15:1-11. doi: 10.1080/14737140.2024.2343338. Online ahead of print.ABSTRACTINTRODUCTION: Statins, in the role of anti-cancer agents, have been used in many types of cancers with results in some cases promising while, in others, disappointing.AREAS COVERED: The purpose of this review is to identify and highlight data from literature on the successes or failure of using statins as anti-cancer agents. We asked ourselves the following two questions:1. Could statins, which are taken mostly to reduce cardiovascular risk, guarantee a lower incidence or a better cancer disease prognosis, concer...
Source: Expert Review of Anticancer Therapy - April 12, 2024 Category: Cancer & Oncology Authors: Luca Filaferro Fabiana Zaccarelli Giovanni Francesco Niccolini Andrea Colizza Federica Zoccali Michele Grasso Massimo Fusconi Source Type: research

Targeting GPRC5D in multiple myeloma
Expert Rev Anticancer Ther. 2024 Apr 12. doi: 10.1080/14737140.2024.2343114. Online ahead of print.ABSTRACTINTRODUCTION: The prognosis of multiple myeloma (MM) continues to improve. Recent progress in therapies, using immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and anti-CD38 monoclonal antibodies, has greatly improved patients' outcomes. Despite these advancements, relapses still happen often, and patients can become resistant to the usual treatments. Newer treatments, such as chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies (BsAbs) targeting B-cell maturation antigen (BCMA), have r...
Source: Expert Review of Anticancer Therapy - April 12, 2024 Category: Cancer & Oncology Authors: Shatha Elemian Samer Al Hadidi Source Type: research